Alcoholic Hepatitis - Pipeline Review, H1 2018

  • ID: 4479908
  • Report
  • 69 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • DURECT Corp
  • Gilead Sciences Inc
  • GRI Bio Inc
  • Immuron Ltd
  • Promethera Biosciences SA
  • Verlyx Pharma Inc
  • MORE
Alcoholic Hepatitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H1 2018, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape.

Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever and fatigue. Risk factors include alcohol use, obesity and genetic factors. Treatment includes corticosteroids and liver transplant.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Alcoholic Hepatitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcoholic Hepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Alcoholic Hepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alcoholic Hepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alcoholic Hepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alcoholic Hepatitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alcoholic Hepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • DURECT Corp
  • Gilead Sciences Inc
  • GRI Bio Inc
  • Immuron Ltd
  • Promethera Biosciences SA
  • Verlyx Pharma Inc
  • MORE
Introduction

Report Coverage

Alcoholic Hepatitis - Overview

Alcoholic Hepatitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Alcoholic Hepatitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alcoholic Hepatitis - Companies Involved in Therapeutics Development

DURECT Corp

Generon (Shanghai) Corp Ltd

Gilead Sciences Inc

GRI Bio Inc

Immuron Ltd

Intercept Pharmaceuticals Inc

Promethera Biosciences SA

Verlyx Pharma Inc

Vital Therapies Inc

Alcoholic Hepatitis - Drug Profiles

AF-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Liver Failure and Alcoholic Hepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DUR-928 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-652 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRI-0621 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HepaStem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-124E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obeticholic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentamidine isethionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMKM-02GI1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selonsertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-4A32 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alcoholic Hepatitis - Dormant Projects

Alcoholic Hepatitis - Product Development Milestones

Featured News & Press Releases

Jun 05, 2017: Vital Therapies Announces Characteristics of Early Subjects in VTL-308 Pivotal Study of ELAD System in Severe Alcoholic Hepatitis

May 23, 2016: Vital Therapies Enrolls First Subject in VTL-

Nov 23, 2015: Generon Collaborating with Mayo Clinic to Initiate a Phase IIa Study with F-652, a First-in-Class Biologic, to Treat Patients with Alcoholic Hepatitis

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Alcoholic Hepatitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Alcoholic Hepatitis - Pipeline by DURECT Corp, H1 2018

Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corp Ltd, H1 2018

Alcoholic Hepatitis - Pipeline by Gilead Sciences Inc, H1 2018

Alcoholic Hepatitis - Pipeline by GRI Bio Inc, H1 2018

Alcoholic Hepatitis - Pipeline by Immuron Ltd, H1 2018

Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals Inc, H1 2018

Alcoholic Hepatitis - Pipeline by Promethera Biosciences SA, H1 2018

Alcoholic Hepatitis - Pipeline by Verlyx Pharma Inc, H1 2018

Alcoholic Hepatitis - Pipeline by Vital Therapies Inc, H1 2018

Alcoholic Hepatitis - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Alcoholic Hepatitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • DURECT Corp
  • Generon (Shanghai) Corp Ltd
  • Gilead Sciences Inc
  • GRI Bio Inc
  • Immuron Ltd
  • Intercept Pharmaceuticals Inc
  • Promethera Biosciences SA
  • Verlyx Pharma Inc
  • Vital Therapies Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll